Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Eli Lilly and Company's score of 38 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Eli Lilly and Company reported total carbon emissions of approximately 5,139,500,000 kg CO2e, comprising 182,000,000 kg CO2e from Scope 1, 345,000,000 kg CO2e from Scope 2, and 5,139,500,000 kg CO2e from Scope 3 emissions. The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Historically, Eli Lilly's emissions have shown fluctuations, with significant emissions recorded in previous years, such as 2019, when total emissions were about 788,000,000 kg CO2e. The company has reported emissions across all three scopes, indicating a comprehensive approach to tracking its environmental impact. Eli Lilly's climate commitments align with industry standards, focusing on transparency and accountability in emissions reporting. However, the absence of specific reduction targets suggests an opportunity for the company to enhance its climate strategy and contribute more effectively to global sustainability efforts.
Access structured emissions data, company-specific emission factors, and source documents
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 527,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 14,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.